BioSpace News Archive

The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that seven biopharmaceutical industry partners together with the Loulou Foundation have formed a pre-competitive consortium to direct a key clinical study for the development of disease-modifying therapeutics for CDD.

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced the results of two key retrospective analyses at the American College of Gastroenterology 2021 annual congress.

Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA ® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer

Fulgent Genetics, Inc. today announced that it will release its third quarter 2021 financial results after the market closes on Tuesday November 9, 2021.

Flare Therapeutics today announced the appointment of Daphne Karydas as Chief Operating Officer and Chief Financial Officer, and Michaela Bowden, PhD, as Senior Vice President of Biology and Translation.

Altoida, Inc. the world’s leading Precision Neurology company, announced a collaboration with the Bioinformatics and Human Electrophysiology Laboratory (BiHELab), Department of Informatics at Ionian University.

AnHeart Therapeutics today announced that the first patient has been dosed in the global Phase 2 trial of taletrectinib in ROS1 fusion-positive lung cancer (TRUST-II).

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).

Marinus Pharmaceuticals, Inc . today announced it has joined forces with the Loulou Foundation and six other biotech and pharmaceutical organizations, to undertake a key observational CDD clinical study to better understand the natural history and the utility of various clinical assessments.

CANbridge Pharmaceuticals, Inc. announced that it has entered into a research collaboration and license agreement with Scriptr Global, Inc., for the development of a gene therapy treatment targeting dystrophinopathies.